Maze Therapeutics MAZE
NASDAQ MAZE
$26.16 +0.29 (+1.12%)
As of: Sep 4, 2026 · 3:20 PM EDT

Maze Therapeutics (MAZE) Selling, General & Administrative (2024 - 2026)

Analysis

Maze Therapeutics (MAZE) Selling, General & Administrative (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn 582.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 662.10 Mn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -417.00 Mn
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn 216.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - 110.21 Mn
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn 593.21 Mn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn 347.92 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - 161.89 Mn
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn 247.47 Mn
10 Maze Therapeutics 1.54 Bn 1.54 Bn - 13.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.10 Mn
Mar 31, 2026 12.41 Mn
Dec 31, 2025 10.49 Mn
Sep 30, 2025 7.78 Mn
Jun 30, 2025 8.37 Mn
Mar 31, 2025 7.82 Mn
Dec 31, 2024 7.51 Mn
Sep 30, 2024 6.87 Mn
Jun 30, 2024 5.90 Mn
Mar 31, 2024 6.14 Mn